- Home
- GHI vs VNDA Comparison
GHI vs VNDA Comparison
Compare GHI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | VNDA |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 289.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | GHI | VNDA |
|---|---|---|
| Price | $6.43 | $6.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $13.00 | ★ $14.00 |
| AVG Volume (30 Days) | 155.1K | ★ 1.3M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 22.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $26,247,399.00 | ★ $212,074,000.00 |
| Revenue This Year | $201.02 | $12.01 |
| Revenue Next Year | $2.87 | $21.57 |
| P/E Ratio | $38.77 | ★ N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $6.01 | $3.81 |
| 52 Week High | $13.29 | $6.88 |
Technical Indicators
Market Signals| Indicator | GHI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 66.91 |
| Support Level | $6.46 | $6.15 |
| Resistance Level | $6.73 | $6.88 |
| Average True Range (ATR) | 0.28 | 0.41 |
| MACD | 0.08 | 0.15 |
| Stochastic Oscillator | 18.50 | 84.98 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.